Individual Patient Expanded Access for Use of Gilteritinib (ASP2215) for Patient Y.A.

Trial Profile

Individual Patient Expanded Access for Use of Gilteritinib (ASP2215) for Patient Y.A.

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 20 Apr 2018

At a glance

  • Drugs Gilteritinib (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Expanded access; Therapeutic Use
  • Most Recent Events

    • 13 Apr 2018 Status changed from recruiting to completed.
    • 25 Oct 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top